F18-FDG Coincidence-PET in Patients with Suspected Gynecological Malignancy

References

• Ak I., Özalp S., Yalçın O. T., Zor E., Vardareli E. Uptake of 2-(18F)fluoro-2-deoxy-D-glucose in uterine leiomyoma: imaging of four patients by coincidence positron emission tomography. Nucl Med Commun 2004; 25: 941–5
   PubMed Web of Science ®Google Scholar
• Bragg D. G., Hricak H. Imaging in gynaecologic malignancies. Cancer 1993; 71 Suppl 4: 1648–51
   Web of Science ®Google Scholar
• Bristow R. E., del Carmen M. G., Pannu H. K., Cohade C., Zahhurak M. L., Fishman E. K., et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90: 519–28
   PubMed Web of Science ®Google Scholar
• Diaz-Montes T. P., Jacene H. A., Wahl R. L., Bristow R. E. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecol Oncol 2005; 98: 510–12
   PubMed Web of Science ®Google Scholar
• Disaia P. J., Creasman W. T. The adnexal mass and early ovarian cancer. Clinical gynaecologic oncology, 6th edn. St. Louis: Mosby 2002; 10: 259–88
   Google Scholar
• Fenchel S., Grab D., Nuessle K., Kotzkerke J., Rieber A., Kreienberg A., et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223: 780–8
   PubMed Web of Science ®Google Scholar
• Hany T. F., Steinert H. C., Goerres G. W., Buck A., von Schulthess G. K. PET diagnostic accuracy: improvement with in-line PET-CT system – initial results. Radiology 2002; 225: 575–81
   PubMed Web of Science ®Google Scholar
• Hubner K. F., McDonald T. W., Niethammer J. G., Smith G. T., Gould H. R., Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-(18F) deoxyglucose (2-(18F) FDG). Gynecol Oncol 1993; 51: 197–204
   PubMed Web of Science ®Google Scholar
• Isonishi S. Biomarker in gynecologic malignancies. Gan To Kagaku Ryoho 2004; 31: 1003–7
   PubMedGoogle Scholar
• Kao C. FDG uptake in a huge uterine myoma. Clin Nucl Med 2003; 28: 249
   PubMed Web of Science ®Google Scholar
• Kerrou K., Montravers F., Grahek D., Younsi N., de Beco V., Talbot J. N. Detection of recurrence of ovarian cancer using (F-18)-FDG scan performed on a dual-head coincidence gamma camera (CDET). Clin Positron Imaging 2000; 3: 186
   PubMedGoogle Scholar
• Kluetz P. G., Meltzer C. C., Villemagne V. L., Kinahan P. E., Chander S., Marinelli M. A., et al. Combined PET-CT imaging in oncology: impact on patient management. Clin Positron Imaging 2000; 3: 223–30
   PubMedGoogle Scholar
• Kubik-Huch R. A., Dorffler W., von Schulthess G. K., Marincek B., Kochli O. R., Seifert B., et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10: 761–7
   PubMed Web of Science ®Google Scholar
• Kurokawa T., Yoshida Y., Kawahara K., Tsuchida T., Fujibayashi Y., Yonekura Y., et al. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range. Ann Nucl Med 2002; 16: 491–3
   PubMed Web of Science ®Google Scholar
• Koga H., Sasaki M., Kuwabara Y., Nakagawa M., Hayashi K., Kaneko K., et al. Lesion detectability of a gamma camera based coincidence system with FDG in patients with malignant tumors: a comparison with dedicated positron emission tomography. Ann Nucl Med 2004; 18: 131–6
   PubMed Web of Science ®Google Scholar
• Lieberman G., MacLean A. B., Buscombe J. R., Hilson A. J., Adamson K., Reid W. M., et al. The clinical application of a dual head gamma camera with coincidence detection in 20 women with suspected ovarian cancer. BJOG 2001; 108: 1229–36
   PubMed Web of Science ®Google Scholar
• Makhija S., Howden N., Edwards R., Kelley J., Townsend D. W., Meltzer C. C. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002; 85: 53–8
   PubMed Web of Science ®Google Scholar
• Muck B., Hommel G. The glycogen content of blood and uterine tissue in women with myoma and endometriosis (author’s transl). Arch Gynakol 1976; 221: 129–37
   PubMedGoogle Scholar
• Nanni C., Rubello D., Farsad M., De Iaco P., Sansovini M., Erba P., et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005; 31: 792–7
   PubMed Web of Science ®Google Scholar
• Pannu H. K., Cohade C., Bristow R. E., Fishman E. K., Wahl R. L. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging 2004; 29: 398–403
   PubMedGoogle Scholar
• Romer W., Avril N., Dose J., Ziegler S., Kuhn W., Herz M., et al. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose. Rofo 1997; 166: 62–8
   PubMedGoogle Scholar
• Schroder W., Zimny M., Rudlowski C., Bull U., Rath W. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999; 9: 117–22
   PubMed Web of Science ®Google Scholar
• Shreve P., Steventon R., Deters E., Kison P., Gross M., Wahl R. Oncologic diagnosis with 2-(fluorine-18)fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998; 207: 431–7
   PubMed Web of Science ®Google Scholar
• Stokkel M., Terhaard C., Mertens I., Hordijk G., van Rijk P. Fluorine-18-FDG detection of laryngeal cancer postradiotherapy using dual-head coincidence imaging. J Nucl Med 1998; 39: 1385–7
   PubMed Web of Science ®Google Scholar
• Tatsumi M., Yutani K., Watanabe Y., Miyoshi S., Tomiyama N., Johkoh T., et al. Feasibility of fluorodeoxyglucose dualhead gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 1999; 40: 566–73
   PubMed Web of Science ®Google Scholar
• Valentin L. Negative F18-FDG cases may be early stage ovarian cancer or borderline disease while F18-FDG accumulating masses may be inflammatory originated. Best Pract Res Clin Obstet Gynaecol 2004; 18: 71–89
   PubMed Web of Science ®Google Scholar
• Yuan C. C., Liu R. S., Wang P. H., Ng H. T., Yeh S. H. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report. J Reprod Med 1999; 44: 775–8
   PubMed Web of Science ®Google Scholar
• Yoshida Y., Kurokawa T., Kawahara K., Tsuchida T., Okazawa H., Fujibayashi Y., et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am J Roentgenol 2004; 182: 227–33
   PubMed Web of Science ®Google Scholar
• Zhang H., Tian M., Oriuchi N., Higuchi T., Tanada S., Endo K. Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET. Br J Radiol 2002; 75: 409–16
   PubMed Web of Science ®Google Scholar